These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 28281205)
1. Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2. Sjöstedt N; van den Heuvel JJMW; Koenderink JB; Kidron H Pharm Res; 2017 Aug; 34(8):1626-1636. PubMed ID: 28281205 [TBL] [Abstract][Full Text] [Related]
2. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Tamura A; Watanabe M; Saito H; Nakagawa H; Kamachi T; Okura I; Ishikawa T Mol Pharmacol; 2006 Jul; 70(1):287-96. PubMed ID: 16608919 [TBL] [Abstract][Full Text] [Related]
3. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Tamura A; Wakabayashi K; Onishi Y; Takeda M; Ikegami Y; Sawada S; Tsuji M; Matsuda Y; Ishikawa T Cancer Sci; 2007 Feb; 98(2):231-9. PubMed ID: 17297656 [TBL] [Abstract][Full Text] [Related]
4. In vitro identification of decreased function phenotype ABCG2 variants. Suominen L; Sjöstedt N; Vellonen KS; Gynther M; Auriola S; Kidron H Eur J Pharm Sci; 2023 Sep; 188():106527. PubMed ID: 37451410 [TBL] [Abstract][Full Text] [Related]
5. Functional analysis of SNPs variants of BCRP/ABCG2. Kondo C; Suzuki H; Itoda M; Ozawa S; Sawada J; Kobayashi D; Ieiri I; Mine K; Ohtsubo K; Sugiyama Y Pharm Res; 2004 Oct; 21(10):1895-903. PubMed ID: 15553238 [TBL] [Abstract][Full Text] [Related]
6. Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan. Deppe S; Ripperger A; Weiss J; Ergün S; Benndorf RA Biochem Biophys Res Commun; 2014 Jan; 443(4):1211-7. PubMed ID: 24388985 [TBL] [Abstract][Full Text] [Related]
7. Clinically relevant mutations in the ABCG2 transporter uncovered by genetic analysis linked to erythrocyte membrane protein expression. Zámbó B; Bartos Z; Mózner O; Szabó E; Várady G; Poór G; Pálinkás M; Andrikovics H; Hegedűs T; Homolya L; Sarkadi B Sci Rep; 2018 May; 8(1):7487. PubMed ID: 29749379 [TBL] [Abstract][Full Text] [Related]
8. Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugs. Zhang W; Yang Y; Dong Z; Shi Z; Zhang JT J Biol Chem; 2019 Dec; 294(52):20222-20232. PubMed ID: 31719146 [TBL] [Abstract][Full Text] [Related]
9. ABCG2 as a therapeutic target candidate for gout. Fujita K; Ichida K Expert Opin Ther Targets; 2018 Feb; 22(2):123-129. PubMed ID: 29264928 [TBL] [Abstract][Full Text] [Related]
10. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Mizuarai S; Aozasa N; Kotani H Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175 [TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Tamura A; Onishi Y; An R; Koshiba S; Wakabayashi K; Hoshijima K; Priebe W; Yoshida T; Kometani S; Matsubara T; Mikuriya K; Ishikawa T Drug Metab Pharmacokinet; 2007 Dec; 22(6):428-40. PubMed ID: 18159130 [TBL] [Abstract][Full Text] [Related]
13. Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. Nakagawa H; Tamura A; Wakabayashi K; Hoshijima K; Komada M; Yoshida T; Kometani S; Matsubara T; Mikuriya K; Ishikawa T Biochem J; 2008 May; 411(3):623-31. PubMed ID: 18237272 [TBL] [Abstract][Full Text] [Related]
14. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2. Ripperger A; Benndorf RA Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388 [TBL] [Abstract][Full Text] [Related]
15. Effects of the gout-causing Q141K polymorphism and a CFTR ΔF508 mimicking mutation on the processing and stability of the ABCG2 protein. Sarankó H; Tordai H; Telbisz Á; Özvegy-Laczka C; Erdős G; Sarkadi B; Hegedűs T Biochem Biophys Res Commun; 2013 Jul; 437(1):140-5. PubMed ID: 23800412 [TBL] [Abstract][Full Text] [Related]
16. Residues contributing to drug transport by ABCG2 are localised to multiple drug-binding pockets. Cox MH; Kapoor P; Briggs DA; Kerr ID Biochem J; 2018 May; 475(9):1553-1567. PubMed ID: 29661915 [TBL] [Abstract][Full Text] [Related]
17. Cellular Processing of the ABCG2 Transporter-Potential Effects on Gout and Drug Metabolism. Mózner O; Bartos Z; Zámbó B; Homolya L; Hegedűs T; Sarkadi B Cells; 2019 Oct; 8(10):. PubMed ID: 31597297 [TBL] [Abstract][Full Text] [Related]
18. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma. Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687 [TBL] [Abstract][Full Text] [Related]
19. The ABCG2/BCRP transporter and its variants - from structure to pathology. Sarkadi B; Homolya L; Hegedűs T FEBS Lett; 2020 Dec; 594(23):4012-4034. PubMed ID: 33015850 [TBL] [Abstract][Full Text] [Related]
20. Cellular expression and function of naturally occurring variants of the human ABCG2 multidrug transporter. Zámbó B; Mózner O; Bartos Z; Török G; Várady G; Telbisz Á; Homolya L; Orbán TI; Sarkadi B Cell Mol Life Sci; 2020 Jan; 77(2):365-378. PubMed ID: 31254042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]